 Edward Janoff
Concepts (583)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcus pneumoniae | 39 | 2024 | 169 | 5.670 |
Why?
| | HIV-1 | 39 | 2024 | 864 | 4.620 |
Why?
| | Pneumococcal Infections | 21 | 2024 | 115 | 4.390 |
Why?
| | HIV Infections | 50 | 2025 | 2836 | 3.820 |
Why?
| | Immunoglobulin G | 36 | 2024 | 893 | 3.090 |
Why?
| | Antibodies, Bacterial | 26 | 2024 | 146 | 3.090 |
Why?
| | Meningitis, Cryptococcal | 10 | 2025 | 30 | 3.060 |
Why?
| | Pneumococcal Vaccines | 23 | 2021 | 142 | 2.800 |
Why?
| | Immunoglobulin A | 23 | 2022 | 211 | 2.700 |
Why?
| | AIDS-Related Opportunistic Infections | 15 | 2021 | 127 | 2.110 |
Why?
| | Bacterial Vaccines | 16 | 2000 | 63 | 1.830 |
Why?
| | B-Lymphocytes | 10 | 2024 | 847 | 1.540 |
Why?
| | Milk, Human | 9 | 2015 | 158 | 1.490 |
Why?
| | Acquired Immunodeficiency Syndrome | 19 | 2014 | 230 | 1.490 |
Why?
| | Cerebrospinal Fluid | 4 | 2025 | 92 | 1.380 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 5 | 2016 | 18 | 1.200 |
Why?
| | Vaccines, Conjugate | 8 | 2021 | 65 | 1.140 |
Why?
| | Lymphocyte Activation | 8 | 2021 | 1142 | 1.070 |
Why?
| | Intestinal Mucosa | 7 | 2015 | 623 | 0.990 |
Why?
| | Infectious Disease Transmission, Vertical | 5 | 2015 | 184 | 0.980 |
Why?
| | Serine Endopeptidases | 6 | 2022 | 123 | 0.980 |
Why?
| | Viremia | 2 | 2018 | 138 | 0.950 |
Why?
| | Immunoglobulin Variable Region | 4 | 2014 | 80 | 0.910 |
Why?
| | Nasopharynx | 2 | 2024 | 76 | 0.900 |
Why?
| | Antifungal Agents | 6 | 2025 | 136 | 0.890 |
Why?
| | Microbiota | 3 | 2024 | 762 | 0.880 |
Why?
| | Pneumonia, Pneumococcal | 8 | 2007 | 48 | 0.870 |
Why?
| | Polysaccharides, Bacterial | 6 | 2007 | 70 | 0.870 |
Why?
| | Bacterial Capsules | 7 | 2014 | 30 | 0.850 |
Why?
| | Vaccination | 11 | 2021 | 1381 | 0.830 |
Why?
| | Antibodies, Viral | 3 | 2025 | 625 | 0.800 |
Why?
| | Adaptive Immunity | 4 | 2021 | 165 | 0.800 |
Why?
| | Diarrhea | 12 | 1997 | 184 | 0.770 |
Why?
| | Plasma Cells | 4 | 2017 | 71 | 0.760 |
Why?
| | Streptolysins | 6 | 1998 | 10 | 0.760 |
Why?
| | Haemophilus Vaccines | 4 | 2014 | 30 | 0.750 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2014 | 394 | 0.740 |
Why?
| | Immunity, Innate | 8 | 2016 | 828 | 0.720 |
Why?
| | Penicillin Resistance | 3 | 2017 | 8 | 0.720 |
Why?
| | Humans | 144 | 2025 | 137585 | 0.700 |
Why?
| | Adult | 64 | 2025 | 37929 | 0.700 |
Why?
| | Cell Compartmentation | 1 | 2020 | 52 | 0.660 |
Why?
| | Antibody Affinity | 5 | 2014 | 60 | 0.660 |
Why?
| | Immunoglobulin M | 13 | 2017 | 289 | 0.650 |
Why?
| | Pneumonia | 2 | 2023 | 639 | 0.630 |
Why?
| | Antibodies, Neutralizing | 3 | 2025 | 286 | 0.630 |
Why?
| | Female | 73 | 2025 | 73304 | 0.630 |
Why?
| | Immunoglobulin D | 2 | 2017 | 30 | 0.600 |
Why?
| | Immunity, Humoral | 2 | 2022 | 116 | 0.590 |
Why?
| | Uganda | 11 | 2025 | 77 | 0.570 |
Why?
| | Breast Feeding | 4 | 2017 | 440 | 0.570 |
Why?
| | Anti-Retroviral Agents | 3 | 2014 | 233 | 0.560 |
Why?
| | HIV Antibodies | 6 | 2014 | 62 | 0.560 |
Why?
| | Male | 62 | 2025 | 67762 | 0.540 |
Why?
| | Case-Control Studies | 13 | 2024 | 3556 | 0.540 |
Why?
| | Middle Aged | 39 | 2025 | 33479 | 0.540 |
Why?
| | Serogroup | 1 | 2017 | 44 | 0.530 |
Why?
| | Nasal Polyps | 1 | 2017 | 59 | 0.530 |
Why?
| | Down Syndrome | 1 | 2023 | 496 | 0.510 |
Why?
| | Neurosurgical Procedures | 1 | 2018 | 197 | 0.500 |
Why?
| | Antibodies, Monoclonal | 6 | 2020 | 1430 | 0.500 |
Why?
| | Dendritic Cells | 2 | 2016 | 483 | 0.490 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2016 | 143 | 0.490 |
Why?
| | CD4-Positive T-Lymphocytes | 6 | 2017 | 1091 | 0.490 |
Why?
| | Sinusitis | 2 | 2017 | 221 | 0.490 |
Why?
| | Rhinitis | 1 | 2017 | 158 | 0.490 |
Why?
| | Disease | 1 | 2016 | 98 | 0.490 |
Why?
| | Infant, Newborn | 14 | 2023 | 6079 | 0.480 |
Why?
| | Anti-HIV Agents | 6 | 2016 | 778 | 0.470 |
Why?
| | Haemophilus influenzae type b | 1 | 2014 | 12 | 0.450 |
Why?
| | Immunoglobulins | 5 | 2007 | 171 | 0.440 |
Why?
| | Giardia | 7 | 1990 | 9 | 0.440 |
Why?
| | Metagenome | 2 | 2012 | 147 | 0.440 |
Why?
| | Giardiasis | 7 | 1990 | 21 | 0.430 |
Why?
| | Intestines | 3 | 2017 | 357 | 0.430 |
Why?
| | T-Lymphocytes | 6 | 2018 | 1996 | 0.430 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2013 | 3 | 0.430 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 257 | 0.430 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.430 |
Why?
| | Immunoglobulin A, Secretory | 5 | 2011 | 9 | 0.420 |
Why?
| | Bacterial Adhesion | 4 | 2019 | 100 | 0.420 |
Why?
| | Burns | 1 | 2018 | 325 | 0.420 |
Why?
| | Antibody Specificity | 7 | 2013 | 189 | 0.410 |
Why?
| | Cryptococcus neoformans | 2 | 2010 | 21 | 0.410 |
Why?
| | Bacterial Proteins | 11 | 2019 | 879 | 0.410 |
Why?
| | Genitalia, Female | 2 | 2012 | 38 | 0.400 |
Why?
| | Antibody Formation | 5 | 2016 | 298 | 0.400 |
Why?
| | Immunocompromised Host | 2 | 2009 | 202 | 0.390 |
Why?
| | Cytokines | 7 | 2025 | 2085 | 0.380 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2024 | 549 | 0.380 |
Why?
| | Cytotoxins | 4 | 1996 | 16 | 0.370 |
Why?
| | RNA, Viral | 7 | 2025 | 656 | 0.350 |
Why?
| | HIV Seropositivity | 5 | 2002 | 125 | 0.350 |
Why?
| | Pneumonia, Bacterial | 3 | 2004 | 116 | 0.340 |
Why?
| | Bacteremia | 3 | 1999 | 214 | 0.340 |
Why?
| | Infant | 17 | 2024 | 9465 | 0.340 |
Why?
| | Mouth Mucosa | 4 | 2011 | 92 | 0.340 |
Why?
| | Antibodies, Fungal | 1 | 2010 | 9 | 0.330 |
Why?
| | Vagina | 1 | 2012 | 187 | 0.330 |
Why?
| | Antiviral Agents | 3 | 2009 | 744 | 0.320 |
Why?
| | Viral Load | 6 | 2020 | 466 | 0.310 |
Why?
| | Amphotericin B | 4 | 2014 | 31 | 0.300 |
Why?
| | Aging | 6 | 2010 | 1864 | 0.300 |
Why?
| | Influenza, Human | 3 | 2009 | 622 | 0.300 |
Why?
| | DNA-Binding Proteins | 1 | 2016 | 1502 | 0.300 |
Why?
| | Mycoses | 4 | 2014 | 79 | 0.290 |
Why?
| | Young Adult | 11 | 2025 | 13209 | 0.290 |
Why?
| | Transcription Factors | 1 | 2016 | 1719 | 0.280 |
Why?
| | Influenza Vaccines | 3 | 2009 | 539 | 0.280 |
Why?
| | Aged | 25 | 2025 | 23961 | 0.280 |
Why?
| | Immunization, Passive | 2 | 2025 | 90 | 0.280 |
Why?
| | Immunity, Mucosal | 4 | 2011 | 97 | 0.280 |
Why?
| | Lipoproteins, IDL | 1 | 2007 | 1 | 0.280 |
Why?
| | Double-Blind Method | 4 | 2025 | 1993 | 0.270 |
Why?
| | Hospitalization | 6 | 2025 | 2199 | 0.270 |
Why?
| | Prospective Studies | 12 | 2018 | 7604 | 0.260 |
Why?
| | Lipoproteins, LDL | 1 | 2007 | 116 | 0.260 |
Why?
| | Immunologic Memory | 4 | 2017 | 353 | 0.240 |
Why?
| | Antibodies, Protozoan | 4 | 1990 | 36 | 0.240 |
Why?
| | Gene Expression | 3 | 2017 | 1502 | 0.240 |
Why?
| | Bacterial Toxins | 3 | 1995 | 106 | 0.240 |
Why?
| | Bacteria | 1 | 2012 | 858 | 0.240 |
Why?
| | Veterans | 3 | 2025 | 1476 | 0.240 |
Why?
| | Immunoglobulin Heavy Chains | 3 | 2013 | 83 | 0.240 |
Why?
| | Nose | 3 | 2015 | 67 | 0.230 |
Why?
| | Cryptosporidiosis | 3 | 1990 | 21 | 0.230 |
Why?
| | Mutation | 4 | 2014 | 3958 | 0.230 |
Why?
| | Oropharynx | 1 | 2024 | 46 | 0.220 |
Why?
| | Adolescent | 16 | 2024 | 21513 | 0.220 |
Why?
| | Flagellin | 1 | 2024 | 17 | 0.220 |
Why?
| | Virus Replication | 5 | 2008 | 483 | 0.220 |
Why?
| | Child, Preschool | 12 | 2024 | 11074 | 0.220 |
Why?
| | Proteins | 3 | 2001 | 1009 | 0.220 |
Why?
| | Treatment Outcome | 7 | 2025 | 10811 | 0.220 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2004 | 42 | 0.220 |
Why?
| | Enterotoxins | 2 | 1995 | 88 | 0.220 |
Why?
| | Smallpox | 1 | 2003 | 9 | 0.210 |
Why?
| | HIV Seronegativity | 4 | 1995 | 28 | 0.210 |
Why?
| | Diphtheria Toxoid | 3 | 1999 | 11 | 0.210 |
Why?
| | Respiratory Tract Infections | 2 | 2024 | 390 | 0.210 |
Why?
| | Risk Factors | 9 | 2023 | 10388 | 0.210 |
Why?
| | Leukocyte Count | 3 | 2014 | 329 | 0.210 |
Why?
| | Incidence | 2 | 2023 | 2804 | 0.210 |
Why?
| | Genes, Immunoglobulin | 2 | 2000 | 28 | 0.210 |
Why?
| | Interleukin-15 | 1 | 2023 | 98 | 0.210 |
Why?
| | Chemokines | 2 | 2023 | 228 | 0.210 |
Why?
| | Leukocytes | 1 | 2025 | 311 | 0.210 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2021 | 85 | 0.200 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 1 | 2022 | 19 | 0.190 |
Why?
| | Disease Transmission, Infectious | 2 | 2004 | 62 | 0.190 |
Why?
| | Bacterial Infections | 4 | 2016 | 250 | 0.190 |
Why?
| | Interleukins | 2 | 2023 | 250 | 0.190 |
Why?
| | Community-Acquired Infections | 3 | 1999 | 174 | 0.180 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 10 | 0.180 |
Why?
| | Enoxaparin | 1 | 2022 | 63 | 0.180 |
Why?
| | Complement System Proteins | 2 | 2007 | 327 | 0.180 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 30 | 0.180 |
Why?
| | Molecular Sequence Data | 4 | 2013 | 2900 | 0.180 |
Why?
| | Vaginal Discharge | 1 | 2001 | 2 | 0.180 |
Why?
| | Interleukin-10 | 2 | 2021 | 302 | 0.180 |
Why?
| | RNA, Bacterial | 2 | 2012 | 190 | 0.180 |
Why?
| | CD4 Lymphocyte Count | 8 | 2010 | 269 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2002 | 113 | 0.180 |
Why?
| | Gastric Mucosa | 1 | 2001 | 55 | 0.170 |
Why?
| | Cryptosporidium | 3 | 1990 | 13 | 0.170 |
Why?
| | Antigens, Protozoan | 3 | 1989 | 24 | 0.170 |
Why?
| | Crohn Disease | 1 | 2024 | 243 | 0.170 |
Why?
| | Biomarkers | 5 | 2021 | 4149 | 0.170 |
Why?
| | Virus Shedding | 2 | 2011 | 48 | 0.170 |
Why?
| | Protease Inhibitors | 1 | 2020 | 107 | 0.160 |
Why?
| | Salivary Glands | 2 | 1997 | 33 | 0.160 |
Why?
| | Cohort Studies | 8 | 2015 | 5742 | 0.160 |
Why?
| | Cells, Cultured | 7 | 2015 | 4193 | 0.160 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 195 | 0.160 |
Why?
| | Pregnancy | 8 | 2015 | 6763 | 0.160 |
Why?
| | Animals | 25 | 2016 | 36940 | 0.160 |
Why?
| | B-Lymphocyte Subsets | 1 | 2000 | 75 | 0.160 |
Why?
| | Feces | 4 | 1990 | 484 | 0.160 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 7 | 2010 | 852 | 0.150 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2010 | 271 | 0.150 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 87 | 0.150 |
Why?
| | Influenza B virus | 2 | 2009 | 44 | 0.150 |
Why?
| | Phagocytes | 1 | 1999 | 101 | 0.150 |
Why?
| | Coinfection | 1 | 2020 | 137 | 0.150 |
Why?
| | Cross Infection | 2 | 1999 | 256 | 0.150 |
Why?
| | Nitric Oxide | 2 | 2008 | 915 | 0.140 |
Why?
| | Africa | 2 | 2017 | 108 | 0.140 |
Why?
| | Nuclear Family | 1 | 1998 | 54 | 0.140 |
Why?
| | Klebsiella Infections | 1 | 1998 | 26 | 0.140 |
Why?
| | Influenza A virus | 2 | 2009 | 107 | 0.140 |
Why?
| | Cholera | 1 | 1997 | 8 | 0.140 |
Why?
| | Klebsiella pneumoniae | 1 | 1998 | 47 | 0.140 |
Why?
| | Syndecan-1 | 1 | 2017 | 38 | 0.140 |
Why?
| | Endocarditis, Bacterial | 1 | 1998 | 41 | 0.140 |
Why?
| | Candidiasis | 2 | 1995 | 56 | 0.140 |
Why?
| | Aged, 80 and over | 8 | 2008 | 7635 | 0.140 |
Why?
| | Disease Susceptibility | 2 | 2017 | 347 | 0.140 |
Why?
| | Amino Acid Motifs | 2 | 2017 | 225 | 0.130 |
Why?
| | Pharynx | 2 | 1998 | 59 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2018 | 318 | 0.130 |
Why?
| | United States | 7 | 2024 | 14841 | 0.130 |
Why?
| | Lymphopoiesis | 1 | 2017 | 26 | 0.130 |
Why?
| | Mucus | 1 | 2017 | 79 | 0.130 |
Why?
| | Nitric Oxide Synthase | 1 | 1997 | 240 | 0.130 |
Why?
| | Neutralization Tests | 2 | 2013 | 75 | 0.130 |
Why?
| | Receptors, CCR5 | 1 | 2017 | 56 | 0.130 |
Why?
| | Paranasal Sinuses | 1 | 2017 | 80 | 0.130 |
Why?
| | Monocytes | 2 | 2000 | 563 | 0.130 |
Why?
| | Antigens, Bacterial | 3 | 2007 | 127 | 0.130 |
Why?
| | Cell Communication | 1 | 2018 | 315 | 0.130 |
Why?
| | Intestine, Small | 1 | 1997 | 156 | 0.130 |
Why?
| | Immunization | 5 | 2005 | 411 | 0.130 |
Why?
| | Disease Models, Animal | 3 | 2016 | 4295 | 0.120 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1995 | 20 | 0.120 |
Why?
| | Nasal Mucosa | 2 | 2014 | 107 | 0.120 |
Why?
| | Lung | 3 | 2012 | 4060 | 0.120 |
Why?
| | Plasma | 2 | 2012 | 212 | 0.120 |
Why?
| | Gastrointestinal Diseases | 3 | 2001 | 209 | 0.120 |
Why?
| | Protective Factors | 1 | 2015 | 93 | 0.120 |
Why?
| | Virulence Factors | 1 | 2017 | 167 | 0.120 |
Why?
| | Time Factors | 11 | 2012 | 6828 | 0.120 |
Why?
| | Measles | 1 | 1995 | 46 | 0.120 |
Why?
| | Critical Illness | 2 | 2018 | 811 | 0.120 |
Why?
| | Pregnancy Trimester, First | 1 | 2015 | 140 | 0.120 |
Why?
| | Prevalence | 3 | 2017 | 2734 | 0.120 |
Why?
| | Blood Cells | 1 | 2014 | 40 | 0.110 |
Why?
| | Adjuvants, Immunologic | 1 | 2016 | 226 | 0.110 |
Why?
| | Clostridium | 1 | 1994 | 17 | 0.110 |
Why?
| | DNA, Bacterial | 3 | 2012 | 337 | 0.110 |
Why?
| | Mice | 7 | 2016 | 17787 | 0.110 |
Why?
| | Intestinal Diseases, Parasitic | 3 | 1989 | 12 | 0.110 |
Why?
| | Type C Phospholipases | 1 | 1994 | 74 | 0.110 |
Why?
| | Complementarity Determining Regions | 1 | 2014 | 51 | 0.110 |
Why?
| | Mutation Rate | 1 | 2014 | 30 | 0.110 |
Why?
| | Carrier State | 2 | 2015 | 67 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 2 | 2024 | 697 | 0.110 |
Why?
| | B-Cell Maturation Antigen | 1 | 2013 | 13 | 0.110 |
Why?
| | Immunoglobulin Class Switching | 1 | 2013 | 20 | 0.110 |
Why?
| | Blood Proteins | 1 | 2015 | 252 | 0.110 |
Why?
| | Cell Line | 4 | 2007 | 2847 | 0.110 |
Why?
| | Clostridium Infections | 1 | 1994 | 73 | 0.100 |
Why?
| | Immunization, Secondary | 2 | 2010 | 87 | 0.100 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 165 | 0.100 |
Why?
| | Chronic Disease | 2 | 2017 | 1793 | 0.100 |
Why?
| | Blood Bactericidal Activity | 3 | 1999 | 36 | 0.100 |
Why?
| | Cytidine Deaminase | 1 | 2013 | 61 | 0.100 |
Why?
| | Child | 8 | 2024 | 21935 | 0.100 |
Why?
| | Phagocytosis | 2 | 2013 | 380 | 0.100 |
Why?
| | Sequence Alignment | 1 | 2013 | 343 | 0.100 |
Why?
| | Cell Count | 1 | 2013 | 324 | 0.100 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1992 | 29 | 0.100 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 307 | 0.100 |
Why?
| | Cytoplasm | 1 | 2013 | 274 | 0.100 |
Why?
| | Predictive Value of Tests | 4 | 2008 | 2031 | 0.100 |
Why?
| | Burkina Faso | 1 | 2012 | 7 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2021 | 1242 | 0.100 |
Why?
| | Nevirapine | 1 | 2012 | 17 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2023 | 15657 | 0.100 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2139 | 0.100 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 234 | 0.100 |
Why?
| | Agglutination | 2 | 2014 | 5 | 0.100 |
Why?
| | Cell Movement | 1 | 2017 | 967 | 0.100 |
Why?
| | Genes, Bacterial | 1 | 2012 | 164 | 0.090 |
Why?
| | Mammary Glands, Human | 1 | 2012 | 64 | 0.090 |
Why?
| | Hydrogen Peroxide | 1 | 1993 | 328 | 0.090 |
Why?
| | Premature Birth | 1 | 2015 | 333 | 0.090 |
Why?
| | HIV Envelope Protein gp120 | 2 | 2013 | 60 | 0.090 |
Why?
| | Saliva | 4 | 2011 | 242 | 0.090 |
Why?
| | Structure-Activity Relationship | 2 | 2007 | 570 | 0.090 |
Why?
| | Morphogenesis | 1 | 2012 | 166 | 0.090 |
Why?
| | Adenovirus Infections, Human | 1 | 1991 | 15 | 0.090 |
Why?
| | Enterocolitis | 1 | 1991 | 17 | 0.090 |
Why?
| | DNA Fingerprinting | 1 | 1991 | 26 | 0.090 |
Why?
| | Inflammation | 2 | 2021 | 2837 | 0.090 |
Why?
| | Pseudomonas | 1 | 1991 | 31 | 0.090 |
Why?
| | Lactation | 1 | 2012 | 181 | 0.090 |
Why?
| | Proteinase Inhibitory Proteins, Secretory | 3 | 2001 | 3 | 0.090 |
Why?
| | Viruses | 1 | 2012 | 113 | 0.090 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 3 | 2001 | 6 | 0.090 |
Why?
| | Multigene Family | 2 | 2002 | 198 | 0.090 |
Why?
| | Virulence | 4 | 1997 | 267 | 0.090 |
Why?
| | Pulmonary Alveoli | 1 | 1993 | 405 | 0.090 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 400 | 0.090 |
Why?
| | Mothers | 1 | 2017 | 754 | 0.080 |
Why?
| | Staphylococcus aureus | 2 | 2015 | 450 | 0.080 |
Why?
| | Mucous Membrane | 1 | 2011 | 125 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2013 | 2833 | 0.080 |
Why?
| | Survival Analysis | 4 | 2025 | 1325 | 0.080 |
Why?
| | Virus Diseases | 3 | 1992 | 212 | 0.080 |
Why?
| | Gene Frequency | 2 | 2002 | 521 | 0.080 |
Why?
| | Tetanus Toxoid | 2 | 2005 | 35 | 0.080 |
Why?
| | Child Day Care Centers | 1 | 1990 | 36 | 0.080 |
Why?
| | Epithelial Cells | 3 | 2008 | 1096 | 0.080 |
Why?
| | Research | 2 | 2010 | 451 | 0.080 |
Why?
| | alpha 1-Antitrypsin | 1 | 2010 | 108 | 0.080 |
Why?
| | Exercise | 1 | 2021 | 2057 | 0.080 |
Why?
| | Immunity, Herd | 1 | 2008 | 5 | 0.080 |
Why?
| | Recombinant Proteins | 2 | 2007 | 1353 | 0.080 |
Why?
| | Infant, Premature | 1 | 2013 | 574 | 0.080 |
Why?
| | Pseudomonas Infections | 1 | 1991 | 225 | 0.070 |
Why?
| | Geriatrics | 1 | 2010 | 98 | 0.070 |
Why?
| | Duodenum | 2 | 2002 | 78 | 0.070 |
Why?
| | Models, Molecular | 3 | 2020 | 1570 | 0.070 |
Why?
| | Anti-Infective Agents | 2 | 2004 | 255 | 0.070 |
Why?
| | Base Sequence | 1 | 2012 | 2181 | 0.070 |
Why?
| | C-Reactive Protein | 2 | 2008 | 410 | 0.070 |
Why?
| | Suicide | 1 | 2015 | 656 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3196 | 0.070 |
Why?
| | Phylogeny | 1 | 2012 | 904 | 0.070 |
Why?
| | Virus Integration | 1 | 2008 | 71 | 0.070 |
Why?
| | Cytomegalovirus Infections | 1 | 1990 | 192 | 0.070 |
Why?
| | Lipids | 2 | 2007 | 672 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 107 | 0.070 |
Why?
| | Opportunistic Infections | 4 | 1992 | 46 | 0.070 |
Why?
| | Botswana | 1 | 2007 | 9 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 1050 | 0.070 |
Why?
| | Coccidia | 1 | 1987 | 1 | 0.070 |
Why?
| | Campylobacter jejuni | 1 | 2007 | 12 | 0.070 |
Why?
| | Evidence-Based Practice | 1 | 2010 | 229 | 0.070 |
Why?
| | Child Development | 1 | 2012 | 475 | 0.070 |
Why?
| | Immunoassay | 1 | 2008 | 115 | 0.070 |
Why?
| | Salivary Proteins and Peptides | 2 | 1997 | 14 | 0.070 |
Why?
| | Helicobacter pylori | 1 | 2007 | 42 | 0.070 |
Why?
| | Urinalysis | 1 | 2007 | 77 | 0.070 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2008 | 141 | 0.070 |
Why?
| | Antigens, Viral | 1 | 2008 | 178 | 0.070 |
Why?
| | Interleukin-6 | 3 | 2021 | 778 | 0.070 |
Why?
| | Serine Proteinase Inhibitors | 2 | 1997 | 47 | 0.070 |
Why?
| | Keratinocytes | 1 | 2008 | 249 | 0.070 |
Why?
| | Haemophilus influenzae | 1 | 2007 | 63 | 0.070 |
Why?
| | Prednisone | 1 | 1987 | 240 | 0.060 |
Why?
| | Sepsis | 1 | 1993 | 617 | 0.060 |
Why?
| | Zidovudine | 2 | 2004 | 78 | 0.060 |
Why?
| | HIV | 1 | 2007 | 234 | 0.060 |
Why?
| | Bronchodilator Agents | 1 | 2008 | 252 | 0.060 |
Why?
| | Methotrexate | 1 | 1987 | 260 | 0.060 |
Why?
| | Neuralgia | 1 | 1987 | 133 | 0.060 |
Why?
| | Ileum | 2 | 1997 | 119 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 1992 | 927 | 0.060 |
Why?
| | Colon | 2 | 2002 | 282 | 0.060 |
Why?
| | HTLV-II Infections | 1 | 2005 | 2 | 0.060 |
Why?
| | Fluconazole | 1 | 2025 | 19 | 0.060 |
Why?
| | Rabbits | 2 | 1997 | 794 | 0.060 |
Why?
| | Secretory Component | 1 | 2004 | 1 | 0.060 |
Why?
| | Neuraminidase | 1 | 2004 | 24 | 0.060 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2004 | 12 | 0.060 |
Why?
| | Immunodominant Epitopes | 1 | 2024 | 27 | 0.060 |
Why?
| | Lactoferrin | 1 | 2004 | 31 | 0.060 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2024 | 17 | 0.060 |
Why?
| | Sweden | 1 | 2024 | 101 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2003 | 23 | 0.050 |
Why?
| | Herpes Zoster | 1 | 1987 | 316 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 34 | 0.050 |
Why?
| | Kinetics | 2 | 1997 | 1670 | 0.050 |
Why?
| | Signal Transduction | 1 | 2016 | 5079 | 0.050 |
Why?
| | Acute Disease | 2 | 1995 | 1007 | 0.050 |
Why?
| | Hemolysis | 2 | 1994 | 206 | 0.050 |
Why?
| | Therapeutic Irrigation | 1 | 2002 | 77 | 0.050 |
Why?
| | Colony Count, Microbial | 2 | 2014 | 120 | 0.050 |
Why?
| | Complement Activation | 2 | 1996 | 415 | 0.050 |
Why?
| | Molecular Weight | 2 | 1995 | 335 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 43 | 0.040 |
Why?
| | Protozoan Infections | 3 | 1992 | 11 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 87 | 0.040 |
Why?
| | Vitamin A | 1 | 2001 | 58 | 0.040 |
Why?
| | Bacterial Typing Techniques | 2 | 2010 | 44 | 0.040 |
Why?
| | Biocatalysis | 1 | 2020 | 56 | 0.040 |
Why?
| | Dysbiosis | 1 | 2022 | 181 | 0.040 |
Why?
| | Thailand | 2 | 1990 | 17 | 0.040 |
Why?
| | Interphase | 1 | 2000 | 32 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2001 | 114 | 0.040 |
Why?
| | Macrophages | 2 | 1999 | 1547 | 0.040 |
Why?
| | State Medicine | 1 | 1980 | 24 | 0.040 |
Why?
| | Respiratory Mucosa | 1 | 2003 | 321 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2000 | 148 | 0.040 |
Why?
| | Blood | 2 | 2004 | 107 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 812 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 179 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 1040 | 0.040 |
Why?
| | Catalytic Domain | 1 | 2020 | 207 | 0.040 |
Why?
| | Macrophage-1 Antigen | 1 | 1999 | 28 | 0.040 |
Why?
| | Gene Products, nef | 1 | 1999 | 12 | 0.040 |
Why?
| | Cryoelectron Microscopy | 1 | 2020 | 190 | 0.040 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1999 | 38 | 0.040 |
Why?
| | Drug Interactions | 1 | 2001 | 410 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2022 | 730 | 0.040 |
Why?
| | Metabolic Diseases | 2 | 2012 | 108 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1627 | 0.040 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 1998 | 60 | 0.040 |
Why?
| | Chemotaxis | 1 | 1999 | 131 | 0.040 |
Why?
| | DNA Restriction Enzymes | 1 | 1998 | 52 | 0.040 |
Why?
| | Colorado | 3 | 1997 | 4565 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 588 | 0.040 |
Why?
| | Exudates and Transudates | 1 | 1998 | 13 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 3 | 2009 | 558 | 0.040 |
Why?
| | Quality Control | 1 | 1998 | 172 | 0.040 |
Why?
| | Molsidomine | 1 | 1997 | 5 | 0.040 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 1997 | 7 | 0.040 |
Why?
| | Vibrio cholerae | 1 | 1997 | 13 | 0.040 |
Why?
| | Cholera Toxin | 1 | 1997 | 32 | 0.040 |
Why?
| | Peru | 1 | 1997 | 58 | 0.030 |
Why?
| | Nitrites | 1 | 1997 | 84 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 1998 | 73 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 664 | 0.030 |
Why?
| | Jejunum | 1 | 1997 | 31 | 0.030 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2019 | 340 | 0.030 |
Why?
| | Muscle, Smooth | 1 | 1997 | 155 | 0.030 |
Why?
| | Cause of Death | 2 | 2014 | 434 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 1997 | 361 | 0.030 |
Why?
| | Catalysis | 1 | 2017 | 307 | 0.030 |
Why?
| | Reference Values | 1 | 1997 | 816 | 0.030 |
Why?
| | Cell Separation | 1 | 1997 | 318 | 0.030 |
Why?
| | Antibiosis | 1 | 2015 | 10 | 0.030 |
Why?
| | Streptococcus mitis | 1 | 2015 | 10 | 0.030 |
Why?
| | Hypokalemia | 1 | 1995 | 24 | 0.030 |
Why?
| | Lactobacillus | 1 | 2015 | 29 | 0.030 |
Why?
| | Antibody-Producing Cells | 1 | 1995 | 30 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 1995 | 55 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 1999 | 900 | 0.030 |
Why?
| | Age Factors | 2 | 1995 | 3295 | 0.030 |
Why?
| | Catalase | 1 | 2015 | 130 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 1996 | 409 | 0.030 |
Why?
| | Kenya | 1 | 1995 | 118 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 1995 | 39 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 1995 | 59 | 0.030 |
Why?
| | Drug Tolerance | 1 | 1995 | 105 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 289 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1995 | 224 | 0.030 |
Why?
| | Potassium | 1 | 1995 | 147 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2010 | 1483 | 0.030 |
Why?
| | Gas Gangrene | 1 | 1994 | 2 | 0.030 |
Why?
| | Complement C5 | 1 | 1995 | 81 | 0.030 |
Why?
| | Immunocompetence | 1 | 1994 | 42 | 0.030 |
Why?
| | Syndrome | 1 | 1995 | 358 | 0.030 |
Why?
| | Cerebrospinal Fluid Otorrhea | 1 | 2014 | 5 | 0.030 |
Why?
| | Transforming Growth Factor beta | 2 | 1994 | 480 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2014 | 52 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 1993 | 1092 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2224 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 840 | 0.030 |
Why?
| | Immune Evasion | 1 | 2014 | 58 | 0.030 |
Why?
| | Neutrophils | 1 | 1999 | 1238 | 0.030 |
Why?
| | South Africa | 1 | 2014 | 222 | 0.030 |
Why?
| | Creatinine | 1 | 1995 | 499 | 0.030 |
Why?
| | Peptide Hydrolases | 1 | 2014 | 111 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 9 | 0.030 |
Why?
| | Pilot Projects | 1 | 1998 | 1710 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2014 | 5757 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1997 | 1738 | 0.020 |
Why?
| | AIDS Vaccines | 1 | 2013 | 52 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2000 | 1991 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1062 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 786 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 385 | 0.020 |
Why?
| | Measles Vaccine | 1 | 1991 | 21 | 0.020 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 1991 | 17 | 0.020 |
Why?
| | Milk | 1 | 2012 | 124 | 0.020 |
Why?
| | Mice, Knockout | 1 | 1998 | 3015 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 585 | 0.020 |
Why?
| | Mammary Glands, Animal | 1 | 2012 | 129 | 0.020 |
Why?
| | Vaccines | 1 | 1996 | 406 | 0.020 |
Why?
| | Gastroenteritis | 2 | 1989 | 69 | 0.020 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1991 | 26 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 27 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2010 | 2828 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2010 | 13 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1991 | 180 | 0.020 |
Why?
| | Rats | 2 | 2004 | 5647 | 0.020 |
Why?
| | Diarrhea, Infantile | 1 | 1990 | 8 | 0.020 |
Why?
| | Institutionalization | 1 | 1990 | 13 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 74 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2607 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2010 | 117 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2074 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.020 |
Why?
| | Cell Survival | 1 | 1993 | 1120 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 152 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2010 | 88 | 0.020 |
Why?
| | Interleukin-17 | 1 | 2010 | 119 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 216 | 0.020 |
Why?
| | Nasal Cavity | 1 | 2010 | 52 | 0.020 |
Why?
| | Sampling Studies | 1 | 1990 | 99 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2012 | 844 | 0.020 |
Why?
| | Health | 1 | 2010 | 84 | 0.020 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2009 | 38 | 0.020 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 77 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2010 | 156 | 0.020 |
Why?
| | Sex Factors | 1 | 1995 | 2071 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 5472 | 0.020 |
Why?
| | Cattle | 1 | 1992 | 984 | 0.020 |
Why?
| | Counterimmunoelectrophoresis | 1 | 1989 | 3 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2012 | 532 | 0.020 |
Why?
| | Cross Reactions | 1 | 1989 | 133 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 726 | 0.020 |
Why?
| | False Positive Reactions | 1 | 1989 | 115 | 0.020 |
Why?
| | Homosexuality | 1 | 1988 | 17 | 0.020 |
Why?
| | Proteomics | 1 | 2015 | 1111 | 0.020 |
Why?
| | Immunization Schedule | 1 | 2010 | 197 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1998 | 5131 | 0.020 |
Why?
| | Qualitative Research | 1 | 2015 | 1386 | 0.020 |
Why?
| | Military Personnel | 1 | 1995 | 544 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2008 | 41 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2008 | 29 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2008 | 145 | 0.020 |
Why?
| | Palatine Tonsil | 1 | 2008 | 48 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 657 | 0.020 |
Why?
| | Forecasting | 1 | 2010 | 389 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2010 | 273 | 0.020 |
Why?
| | Fluticasone | 1 | 2008 | 90 | 0.020 |
Why?
| | Specimen Handling | 1 | 1989 | 183 | 0.020 |
Why?
| | Kidney | 1 | 1995 | 1468 | 0.020 |
Why?
| | Nutritional Status | 1 | 1990 | 350 | 0.020 |
Why?
| | Albuterol | 1 | 2008 | 110 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2008 | 239 | 0.020 |
Why?
| | Immunity | 1 | 2008 | 143 | 0.020 |
Why?
| | Age Distribution | 1 | 2008 | 392 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2010 | 513 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2167 | 0.020 |
Why?
| | Biopsy | 1 | 1991 | 1129 | 0.020 |
Why?
| | Health Resources | 1 | 2008 | 120 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 1060 | 0.020 |
Why?
| | Virus Activation | 1 | 1987 | 88 | 0.020 |
Why?
| | Spirometry | 1 | 2008 | 281 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 351 | 0.020 |
Why?
| | Cough | 1 | 2008 | 122 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2008 | 268 | 0.020 |
Why?
| | Telomere | 1 | 2010 | 280 | 0.020 |
Why?
| | Disease Progression | 3 | 1999 | 2757 | 0.020 |
Why?
| | Hemophilia A | 1 | 1989 | 139 | 0.020 |
Why?
| | Antitubercular Agents | 1 | 2008 | 206 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2008 | 531 | 0.020 |
Why?
| | Biodiversity | 1 | 2010 | 409 | 0.020 |
Why?
| | Fever | 1 | 2008 | 306 | 0.020 |
Why?
| | ROC Curve | 1 | 2008 | 554 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 688 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 1990 | 1509 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 1989 | 395 | 0.020 |
Why?
| | Telomerase | 1 | 2008 | 250 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 500 | 0.020 |
Why?
| | Biomedical Research | 1 | 2012 | 692 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2005 | 43 | 0.020 |
Why?
| | Liver Diseases | 1 | 2008 | 315 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 2005 | 79 | 0.010 |
Why?
| | Immune Tolerance | 1 | 1987 | 363 | 0.010 |
Why?
| | Poverty | 1 | 2008 | 521 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1477 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2008 | 408 | 0.010 |
Why?
| | Perinatal Care | 1 | 2004 | 56 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2004 | 116 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5778 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 652 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2844 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 767 | 0.010 |
Why?
| | Cuba | 1 | 1980 | 12 | 0.010 |
Why?
| | Occupational Health Services | 1 | 1980 | 32 | 0.010 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 11 | 0.010 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 1999 | 19 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 23 | 0.010 |
Why?
| | Macaca | 1 | 1999 | 56 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 1999 | 110 | 0.010 |
Why?
| | Encephalitis, Viral | 1 | 1999 | 43 | 0.010 |
Why?
| | Simian Immunodeficiency Virus | 1 | 1999 | 88 | 0.010 |
Why?
| | Adenoviridae | 1 | 1999 | 193 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2000 | 686 | 0.010 |
Why?
| | Maternal Health Services | 1 | 1980 | 98 | 0.010 |
Why?
| | Deoxycholic Acid | 1 | 1998 | 14 | 0.010 |
Why?
| | Quinine | 1 | 1998 | 20 | 0.010 |
Why?
| | Centrifugation | 1 | 1997 | 30 | 0.010 |
Why?
| | Didanosine | 1 | 1996 | 13 | 0.010 |
Why?
| | Proviruses | 1 | 1996 | 14 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2000 | 1266 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 1996 | 66 | 0.010 |
Why?
| | Mental Health Services | 1 | 1980 | 421 | 0.010 |
Why?
| | DNA, Viral | 1 | 1996 | 364 | 0.010 |
Why?
| | Nucleic Acids | 1 | 1995 | 71 | 0.010 |
Why?
| | Mitosis | 1 | 1995 | 192 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1178 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1946 | 0.010 |
Why?
| | Cell Nucleus | 1 | 1995 | 620 | 0.010 |
Why?
| | Vermont | 1 | 1989 | 9 | 0.000 |
Why?
| | Water Supply | 1 | 1989 | 78 | 0.000 |
Why?
| | Rural Population | 1 | 1989 | 563 | 0.000 |
Why?
|
|
Janoff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|